The cardiac antifibrotic effects of SGLT-2 inhibitors found in rat models with dapagliflozin [51] and in human cardiac fibroblasts with empagliflozin [52] may also explain the protective effect of SGLT-2 inhibitors on HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.